Comparison of a decision analytic model with results from a naturalistic economic clinical trial: An application to evaluating alternative antidepressants

American Journal of Managed Care

Volumn 2, Issue 9, 1996, Pages 1211-1223

  Hylan, Timothy R ^a   Kotsanos, James G ^a,b   Andersen, John S ^a   Brown, Susan H ^a   Copley Merriman, Catherine ^a,c   Egbuonu Davis, Lisa ^a,c   Heiligenstein, John H ^a   Overhage, J Marc ^b   Whiteside, Robert E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000734156     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Barr JT, Schumacher GE. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, ed. Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers, 1996:1197-1214.
2. Glick H, Kinosian B, Schulman K. Decision analytic modeling: Some uses in the evaluation of new pharmaceuticals. Drug Info J 1994;28:691-707.
3. Anton SF, Revicki D. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: A cost-effectiveness study of nefazadone. Psychopharmacol Bull 1995;31:249-258.
4. Bentkover J, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. PharmacoEconomics 1995;8:223-232.
5. Nuijeten MJC, Hardens M, Soutre E. A Markov process analysis comparing the cost-effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. PharmacoEconomics 1995;8:156-168.
6. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost-utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothepin. PharmacoEconomics 1994;5:249-264.
7. Minshall ME, Dawson A. Integrating a global health economics study within a phase III clinical trial. Drug Info J 1995;29:1191-1199.
8. Hylan TR, Andrejasich C, Haley J. The emerging use of economic models in the life-cycle of pharmaceutical products. Am J Man Care 1996;2:671-678.
9. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996;275:1897-1902.
10. Song F, Freemantle N, Sheldon, T. Selective serotonin reuptake inhibitors: Meta-analyses of efficacy and acceptability. BMJ 1993;306:683-687.
11. Workman E, Short D. Atypical antidepressants versus imipramine in the treatment of major depression. J Clin Psychiatry 1993;54:5-12.
12. Montgomery SA, Henry J, McDonald G. Selective serotonin reuptake inhibitors: Meta-Analyses of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
13. Montgomery SA, Kasper S. Comparison of compliance between selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. Int Clin Psychopharmacol 1995;9(Suppl 4):33-40.
14. Montgomery SA. Prophylaxis in recurrent unipolar depression: A new indication for treatment studies. J Psychopharmacol 1989;3:47-53.
15. Mintz J, Mintz LI, Arrudu MJ, Hwang SS. Treatment of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768.
16. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.
17. Eaton WW, Regier DA, Locke BZ, Taube CA. The Epidemiologic Catchment Area program of the National Institute of Mental Health. Public Health Rep 1981;96:319-325.
18. Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technic. N Engl J Med 1973;288:1272-1275.
19. McNamee P, Celona J. Decision Analysis with Super-tree. South San Francisco, CA: The Scientific Press; 1990:31-33.
20. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: Results from the Medical Outcomes Study. JAMA 1989;262:914-919.
21. Relative Values for Physicians, 1991-1992. New York: McGraw Hill; 1991.
22. MDDB-SELECT™. Indianapolis, IN: Medi-Span Development Corporation, 1991.
23. Medical Prevailing Healthcare Charges System. New York: Health Insurance Association of America; 1992.
24. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990;264: 2524-2528.
25. Median weekly earnings of full-time wage and salary workers by age, race, and sex, 1979-88. Handbook of Labor Statistics. Washington, DC: Government Printing Office; 1989:162. Bulletin 2340.
26. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: A cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disorders 1994;31:1-18.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;12:278-296.
28. Derogatis L, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist: A measure of primary symptom dimensions. In: Pichot P, ed. Psychological Measurements in Psychopharmacology: Problems in Psychopharmacology. Basel, Switzerland: Kargerman, 1974:79-110.
29. Ware J, Kosinski M, Keller SD. SF-36 Physical and Mental Component Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
30. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-730.
31. Katzelnick DJ, Kobak K, Jefferson J, et al. Prescribing patterns of antidepressant medications for depression in an HMO. Formulary 1996;31:374-388.
32. Donoghue J, Tylee A. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996:168:164-168.
33. Agency for Health Care Policy and Research. Depression in Primary Care: Vol. 2, Treatment of Major Depression. Rockville, MD: US Department of Health and Human Services; 1993.
34. Kupfer DJ, Frank E, Perel JM. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 1989;46:771-775.
35. Simon G, Wagner E, VonKorff M. Cost-effectiveness comparisons using real-world randomized trials - the case of new antidepressant drugs. J Clin Epidemiol 1995;48: 363-373.
36. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673.
37. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as a strategy for prevention of suicide. BMJ 1994;309:249-253.
38. Stewart A. Antidepressant pharmacotherapy: Cost comparison of SSRIs and TCAs. Br J Med Econ 1994;7:67-79.
39. Priest RG. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients. Clin Ther 1996;18:347-358.
40. Boyer WF, Feighner JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jonsson B, Rosenbaum H, eds. Health Economics of Depression. New York: John Wiley and Sons; 1993.
41. Rittenhouse BE, Luce B. Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippencott-Raven Publishers, 1995:1215-1223.